Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin

Sodium–glucose cotransporter-2 inhibitor combination therapy to optimize glycemic control and tolerability in patients with type 2 diabetes: focus on dapagliflozin–metformin

Stanley S Schwartz,1,2 Arie Katz3 1University of Pennsylvania, Philadelphia, PA, USA; 2Main Line Health System, Ardmore, PA, USA; 3AstraZeneca, Fort Washington, PA, USA Abstract: In type 2 diabetes (T2D), early combination therapy using agents that target a number of the underlying pathophysiologic...

Full description

Bibliographic Details
Main Authors: Schwartz SS, Katz A
Format: Article
Language:English
Published: Dove Medical Press 2016-03-01
Series:Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
Subjects:
combination therapy
dapagliflozin
metformin
Online Access:https://www.dovepress.com/sodiumndashglucose-cotransporter-2-inhibitor-combination-therapy-to-op-peer-reviewed-article-DMSO

Internet

https://www.dovepress.com/sodiumndashglucose-cotransporter-2-inhibitor-combination-therapy-to-op-peer-reviewed-article-DMSO

Similar Items